Hepatitis B Control
Country Profile 2017
## CONTENTS

**Regional Progress: Hepatitis B Vaccination Coverage, 1990–2017**

1

**Regional Progress: Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children**

2

### Country Profiles

<table>
<thead>
<tr>
<th>Country</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Samoa</td>
<td>3</td>
</tr>
<tr>
<td>Australia</td>
<td>4</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>5</td>
</tr>
<tr>
<td>Cambodia</td>
<td>6</td>
</tr>
<tr>
<td>China</td>
<td>7</td>
</tr>
<tr>
<td>China, Hong Kong SAR</td>
<td>8</td>
</tr>
<tr>
<td>China, Macao SAR</td>
<td>9</td>
</tr>
<tr>
<td>Cook Islands</td>
<td>10</td>
</tr>
<tr>
<td>Fiji</td>
<td>11</td>
</tr>
<tr>
<td>French Polynesia</td>
<td>12</td>
</tr>
<tr>
<td>Guam</td>
<td>13</td>
</tr>
<tr>
<td>Japan</td>
<td>14</td>
</tr>
<tr>
<td>Kiribati</td>
<td>15</td>
</tr>
<tr>
<td>Lao People’s Democratic Republic</td>
<td>16</td>
</tr>
<tr>
<td>Malaysia</td>
<td>17</td>
</tr>
<tr>
<td>Marshall Islands</td>
<td>18</td>
</tr>
<tr>
<td>Micronesia (Federated States of)</td>
<td>19</td>
</tr>
<tr>
<td>Mongolia</td>
<td>20</td>
</tr>
<tr>
<td>Nauru</td>
<td>21</td>
</tr>
<tr>
<td>New Caledonia</td>
<td>22</td>
</tr>
<tr>
<td>New Zealand</td>
<td>23</td>
</tr>
<tr>
<td>Niue</td>
<td>24</td>
</tr>
<tr>
<td>Northern Mariana Islands, Commonwealth of the</td>
<td>25</td>
</tr>
<tr>
<td>Palau</td>
<td>26</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>27</td>
</tr>
<tr>
<td>Philippines</td>
<td>28</td>
</tr>
<tr>
<td>Republic of Korea</td>
<td>29</td>
</tr>
<tr>
<td>Samoa</td>
<td>30</td>
</tr>
<tr>
<td>Singapore</td>
<td>31</td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>32</td>
</tr>
<tr>
<td>Tokelau</td>
<td>33</td>
</tr>
<tr>
<td>Tonga</td>
<td>34</td>
</tr>
<tr>
<td>Tuvalu</td>
<td>35</td>
</tr>
<tr>
<td>Vanuatu</td>
<td>36</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>37</td>
</tr>
<tr>
<td>Wallis and Futuna</td>
<td>38</td>
</tr>
<tr>
<td>Mongolia</td>
<td>20</td>
</tr>
</tbody>
</table>
Regional Progress

Hepatitis B vaccination coverage, 1990 – 2017

Source: WHO and UNICEF Joint Reporting Form on Immunization
Regional coverage is based on calculated average among all countries, whether they reported coverage or not.
Regional Progress as of May 2018

Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

© WHO Regional Office for the Western Pacific 2016. All rights reserved
AMERICAN SAMOA

Demographics
- Total population (2017): 55,641
- Births (2011): 1,287
- Surviving infants (2011): 1,278
- Urban population (2016): 87%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1986-1987
- HepB birth dose introduced: 1991
- Current schedule: 0, 1 month, 12 months
- HepB3 type: Monovalent

Vaccination coverage surveys
- 1990: National, 3-4 years, 95, not reported, 82%, not reported
- 1995: National, 7-8 years, 432, 75%, 91%, not reported
- 2016: National, 24-35 months, 1,180, 97%, 82%, 85%

WHO verification
- Status of verifying prevalence targets
  - Verification started: February 2013
  - Decision: <1% in children
  - Decision date: October 2014

Neonatal deliveries

Hepatitis B serological surveys
- 1991: Tutuila, 3-4 years, Community based, 93, 2.2%
- 1995: National, 7-8 years, Community based, 432, 0.5%
- 2011: National, 6 years, School based, 562, 0.2%

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
### Demographics

- **Total population (2017)**: 24,450,561
- **Births (2017)**: 313,981
- **Suriving infants (2017)**: 312,968
- **Urban population (2016)**: 90%

### Hepatitis B vaccine

- **HepB3 introduced nationwide**: 2000
- **HepB birth dose introduced**: 2000
- **Current schedule**: 0, 2 months, 4 months, 6 months
- **HepB3 type**: DTP-Hib-HepB-IPV

### WHO verification

- **Status of verifying prevalence targets**: Verification started: June 2012
- **Decision**: <1% in children
- **Decision date**: December 2012

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>12 months</td>
<td>280,874</td>
<td>not reported</td>
<td>94%</td>
<td>92%</td>
<td>From National Health Insurance covering 99% of population</td>
</tr>
</tbody>
</table>

### Neonatal deliveries

- **Total population (2017)**: 24,450,561
- **Births (2017)**: 313,981
- **Surving infants (2017)**: 312,968
- **Urban population (2016)**: 90%

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>National</td>
<td>1-9 years</td>
<td>Hospital based</td>
<td>249</td>
<td>0.4% (0.0% - 2.2%)</td>
<td>Gidding Vaccine 2007</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
BRUNEI DARUSSALAM

Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>Data 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population</td>
<td>428,697</td>
</tr>
<tr>
<td>Births</td>
<td>6,668</td>
</tr>
<tr>
<td>Surviving infants</td>
<td>6,630</td>
</tr>
<tr>
<td>Urban population</td>
<td>78%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-Hib-HepB-IPV

WHO verification

- Status of verifying prevalence targets
  - Verification started: March 2013
  - Decision: <1% in children
  - Decision date: June 2013

Neonatal deliveries

<table>
<thead>
<tr>
<th>Location</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DPT3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>National average</td>
<td>4513</td>
<td>0.09%</td>
<td></td>
<td></td>
<td>MoH Brunei 2012</td>
</tr>
</tbody>
</table>

Hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Year</th>
<th>Timely HepB BD</th>
<th>Any HepB BD</th>
<th>HepB3</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>90%</td>
<td>93%</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>90%</td>
<td>93%</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>90%</td>
<td>93%</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>90%</td>
<td>93%</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>90%</td>
<td>93%</td>
<td></td>
</tr>
</tbody>
</table>

2017 Districts by coverage categories*

- National average
- Poorest quantile
- Richest quantile

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DPT3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>8-9 years</td>
<td>School based</td>
<td>4513</td>
<td>0.09%</td>
<td></td>
<td>MoH Brunei 2012</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>8-9 years</td>
<td>School based</td>
<td>4513</td>
<td>0.09%</td>
<td>MoH Brunei 2012</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

Total population (2017) 16 005 373
Births (2017) 366 177
Surviving infants (2017) 357 932
Urban population (2016) 21%

Hepatitis B vaccine

HepB3 introduced nationwide 2005
HepB birth dose introduced 2005
Current schedule 0, 6 weeks, 10 weeks, 14 weeks
HepB3 type DTP-Hib-HepB

WHO verification

Status of verifying prevalence targets
Verification started: January 2018
Decision: <1% in children
Decision date: June 2018

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2005 National 12-23 months 1517 not reported 78% DHS Survey
2009 National 12-23 months 1068 61% not reported 56% Cambodia Socio-Economic Survey 2009 (confirmation method only by card)
2010 National 12-23 months 1614 73% 84% 84% DHS Survey: HepB BD 73%, HepB3 85%, DTP3 85% by 12 months
2014 National 12-23 months 1460 83% 84% 84% DHS Survey: HepB BD 83%, HepB3 82%, DTP3 82% by 12 months

Survey year Location Ages enrolled Sample size HBsAg prevalence (95%CI) Reference/Notes
2001 Kg Chhnang 9-17 months Hospital based 900 2.7% Report MoH/PATH/AIHI
2006 National 5 years Community based 1558 3.5% (2.4% - 4.8%) Soeung AMTH 2009
2011 Urban, Rural, Remote 4-5 years Community based 2429 0.3%, 1.4%, 3.5% Mao Vaccine 2013
2017 National 5-6 years Community based 2520 0.6% (0.3% - 1.0%) Cambodia MOH 2017 preliminary data

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
CHINA

Demographics
Total population (2017): 1,409,517,397
Births (2017): 16,521,467
Surviving infants (2017): 16,356,002
Urban population (2016): 57%

Hepatitis B vaccine
HepB3 introduced nationwide: 1992
HepB birth dose introduced: 1992
Current schedule: 0, 1 month, 6 months
HepB3 type: Monovalent

WHO verification
Status of verifying prevalence targets
Verification started: February 2012
Decision: <1% in children
Decision date: June 2012

Neonatal deliveries

Hepatitis B vaccination coverage

2017 Districts by coverage categories

Vaccination coverage surveys
Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2004 National | 12-23 months | 171 188 | not reported | 85% | not reported | The National EPI Evaluation Report 2004 (Confirmation method by card only); 90% HepB3 by 12 months
2006 National | 1 year | 3636 | 93% | 83% | not reported | Liang JID 2009; 2005 birth cohort
2008 National | 12-23 months | 9762 | not reported | 93% | 91% | Analysis Report of National Health Services Survey in China

Hepatitis B serological surveys
Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
2006 National | 1-4 years | Community based | 16 376 | 1.0% (0.8% - 1.2%) | Liang JID 2009
2006 National | 5 years | Community based | 2215 | 1.1% (0.4% - 1.8%) | Liang JID 2009
2006 National | 6 years | Community based | 2356 | 0.9% (0.4% - 1.5%) | Liang JID 2009
2012 National | 1-4 years | Community based | 5474 | 0.5% (0.3% - 0.7%) | Yonghao International Journal of Infectious Diseases 2015
2012 National | 5-9 years | Community based | 4407 | 0.7% (0.5% - 1.0%) | Yonghao International Journal of Infectious Diseases 2015
2012 National | 10-14 years | Community based | 3326 | 1.2% (0.8% - 1.6%) | Yonghao International Journal of Infectious Diseases 2015
2014 National | 1-4 years | Community based | 12 681 | 0.3% (0.2% - 0.5%) | Cui FQ Emerging Infectious Diseases 2017
2014 National | 5-14 years | Community based | 9738 | 0.9% (0.7% - 1.3%) | Cui FQ Emerging Infectious Diseases 2017
2014 National | 15-29 years | Community based | 9294 | 4.4% (3.8% - 5.1%) | Cui FQ Emerging Infectious Diseases 2017

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
### Demographics

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2017)</td>
<td>7,364,883</td>
</tr>
<tr>
<td>Births (2017)</td>
<td>81,714</td>
</tr>
<tr>
<td>Surviving infants (2017)</td>
<td>81,599</td>
</tr>
<tr>
<td>Urban population (2016)</td>
<td>100%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3 introduced nationwide</td>
<td>1988</td>
</tr>
<tr>
<td>HepB birth dose introduced</td>
<td>1988</td>
</tr>
<tr>
<td>Current schedule</td>
<td>0, 1 month, 6 months</td>
</tr>
<tr>
<td>HepB3 type</td>
<td>Monovalent</td>
</tr>
</tbody>
</table>

### WHO verification

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Status of verifying prevalence targets</td>
<td></td>
</tr>
<tr>
<td>Verification started:</td>
<td>February 2011</td>
</tr>
<tr>
<td>Decision:</td>
<td>&lt;1% in children</td>
</tr>
<tr>
<td>Decision date:</td>
<td>July 2011</td>
</tr>
</tbody>
</table>

### Neonatal deliveries

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>National average</td>
<td></td>
</tr>
<tr>
<td>Poorest quantile</td>
<td></td>
</tr>
<tr>
<td>Richest quantile</td>
<td></td>
</tr>
<tr>
<td>National average</td>
<td></td>
</tr>
<tr>
<td>Poorest quantile</td>
<td></td>
</tr>
<tr>
<td>Richest quantile</td>
<td></td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>2-5 years</td>
<td>6248</td>
<td>not reported</td>
<td>&gt;99.5%</td>
<td>&gt;99.8%</td>
<td>MoH Hong Kong 2011</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>2-5 years</td>
<td>not reported</td>
<td>&gt;95.0%</td>
<td>&gt;95.0%</td>
<td>&gt;95.0%</td>
<td>WHO-UNICEF Joint Reporting Form (data for 2017)</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>1-4 years</td>
<td>Laboratory based</td>
<td>196</td>
<td>1%</td>
<td>MoH Hong Kong 2011</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>12-15 years</td>
<td>School based</td>
<td>1913</td>
<td>0.8% (0.4% - 1.2%)</td>
<td>MoH Hong Kong 2011</td>
</tr>
</tbody>
</table>

### Abbreviations

- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

### Sources

- Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from World Bank’s World Development Indicators (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
MACAO SAR (CHINA)

Demographics
- Total population (2017): 622,567
- Births (2017): 7,574
- Surviving infants (2017): 7,554
- Urban population (2016): 100%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1984
- HepB birth dose introduced: 1989
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
---|---|---|---|---|---|---|---
2003 | National | 6-9 years | School based | 437 | 0% (0% - 0.7%) | MoH Macao 2008

WHO verification
- Status of verifying prevalence targets
  - Verification started: April 2008
  - Decision: <1% in children
  - Decision date: August 2008

Neonatal deliveries

Vaccination coverage surveys

Hepatitis B serological surveys
- Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
---|---|---|---|---|---|---
2003 | National | 6-9 years | School based | 437 | 0% (0% - 0.7%) | MoH Macao 2008

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from World Bank’s World Development Indicators (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
COOK ISLANDS

Demographics

<table>
<thead>
<tr>
<th>Total population (2017)</th>
<th>17,380</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2017)</td>
<td>213</td>
</tr>
<tr>
<td>Surviving infants (2017)</td>
<td>211</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>56%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>269</td>
<td>0%</td>
<td></td>
<td></td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

WHO verification

<table>
<thead>
<tr>
<th>Status of verifying prevalence targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verification started: January 2013</td>
</tr>
<tr>
<td>Decision: &lt;1% in children</td>
</tr>
<tr>
<td>Decision date: October 2013</td>
</tr>
</tbody>
</table>

Neonatal deliveries

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>269</td>
<td>0%</td>
<td></td>
<td></td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

Hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>269</td>
<td>0%</td>
<td></td>
<td></td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

2017 Districts by coverage categories*

<table>
<thead>
<tr>
<th>District 2017</th>
<th>HepB3 coverage (%</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>Timely HepB BD</td>
</tr>
<tr>
<td>&lt;50%</td>
<td>Any HepB BD</td>
</tr>
<tr>
<td>&lt;50%-79%</td>
<td>Timely HepB 3</td>
</tr>
<tr>
<td>80%-89%</td>
<td></td>
</tr>
<tr>
<td>90%-94%</td>
<td></td>
</tr>
<tr>
<td>&gt;94%</td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>School based</td>
<td>269</td>
<td>0%</td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
FIJI

Demographics

- Total population (2017): 905,502
- Births (2017): 17,246
- Surviving infants (2017): 17,007
- Urban population (2016): 54%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>National</td>
<td>12-23 months</td>
<td>not reported</td>
<td>not reported</td>
<td>94%</td>
<td>92%</td>
<td>Fiji National EPI Survey</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>12-23 months</td>
<td>630</td>
<td>not reported</td>
<td>92%</td>
<td>83%</td>
<td>Fiji Immunization Coverage Survey Report</td>
</tr>
<tr>
<td>2008</td>
<td>National</td>
<td>15-26 months</td>
<td>1200</td>
<td>86%</td>
<td>99%</td>
<td>99%</td>
<td>Fiji National Immunisation Coverage Survey</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>not reported</td>
<td>not reported</td>
<td>not reported</td>
<td>not reported</td>
<td>91%</td>
<td>WHO-UNICEF Joint Reporting Form (Data for 2014)</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>285</td>
<td>0.7%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2008</td>
<td>Sub-national</td>
<td>6 months-5 years</td>
<td>Community based</td>
<td>428</td>
<td>0%</td>
<td>WHO:RS/2009/GE/23(JPN)</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

Note: HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. HepB3 coverage at national and district level are inconsistent due to different data sources used by Fiji.
FRENCH POLYNESIA

Demographics

- Total population (2017): 283,007
- Births (2017): 4,298
- Surviving infants (2017): 4,273
- Urban population (2016): 56%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1992
- HepB birth dose introduced: 1992
- Current schedule: 0, 2 months, 10 months
- HepB3 type: DTP-Hib-HepB-IPV
- Verification started: February 2016
- Decision: <1% in children
- Decision date: September 2016

Neonatal deliveries

- Total population (2017): 283,007
- Births (2017): 4,298
- Surviving infants (2017): 4,273
- Urban population (2016): 56%
- HepB3 introduced nationwide: 1992
- HepB birth dose introduced: 1992
- Current schedule: 0, 2 months, 10 months
- HepB3 type: DTP-Hib-HepB-IPV
- Verification started: February 2016
- Decision: <1% in children
- Decision date: September 2016

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Austral Island</td>
<td>0-11 months</td>
<td>Community based</td>
<td>957</td>
<td>2.1%</td>
<td>B Trans R Soc Trop 1990</td>
</tr>
<tr>
<td>2013-2014</td>
<td>National</td>
<td>6-7 years</td>
<td>School based</td>
<td>1196</td>
<td>0.0% (0.0%-0.5%)</td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

Hepatitis B vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2017 Districts by coverage categories*

- Verification started: February 2016
- Decision: <1% in children
- Decision date: September 2016

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from World Bank’s World Development Indicators (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
GUAM

Demographics

- Total population (2017): 164,229
- Births (2017): 2,745
- Surviving infants (2017): 2,722
- Urban population (2016): 95%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 1-2 months, 6-18 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: October 2015
  - Decision: <1% in children
  - Decision date: June 2016

Neonatal deliveries

- Proportional of deliveries (%)
  - National average
  - Poorest quantile
  - Richest quantile
  - Attended by SBA
  - In health facility

Hepatitis B vaccination coverage

- Vaccination Coverage (%)
  - Timely HepB BD
  - Any HepB BD
  - HepB3

2017 Districts by coverage categories

- % District 2017

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>National</td>
<td>6 years</td>
<td>School based</td>
<td>1484</td>
<td>0.0%</td>
<td>Guam DoH &amp; Social Services 2015</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from World Bank’s World Development Indicators (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization. HepB birth dose coverage at national and district level are inconsistent due to different data sources used by Guam.
**Demographics**

- **Total population (2017)**: 127,484,450
- **Births (2017)**: 1,033,077
- **Surviving infants (2017)**: 1,031,085
- **Urban population (2016)**: 94%

**Hepatitis B vaccine**

- **HepB3 introduced nationwide**: October 2016
- **HepB birth dose introduced**: If born to HBsAg+ mothers
- **Current schedule**: 2 months, 3 months, 7 months
- **HepB3 type**: Monovalent

**WHO verification**

- **Status of verifying prevalence targets**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

**Neonatal deliveries**

- **Total population (2017)**: 127,484,450
- **Births (2017)**: 1,033,077
- **Surviving infants (2017)**: 1,031,085
- **Urban population (2016)**: 94%

**Hepatitis B vaccination coverage**

- **HepB3 introduced nationwide**: October 2016
- **HepB birth dose introduced**: If born to HBsAg+ mothers
- **Current schedule**: 2 months, 3 months, 7 months
- **HepB3 type**: Monovalent

**2017 Districts by coverage categories**

- **Total population (2017)**: 127,484,450
- **Births (2017)**: 1,033,077
- **Surviving infants (2017)**: 1,031,085
- **Urban population (2016)**: 94%

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>Okinawa</td>
<td>1-4 years</td>
<td>School based</td>
<td>1529</td>
<td>0.1%</td>
<td>Hayashi Int J Epi 1990</td>
</tr>
<tr>
<td>1995-1996</td>
<td>National</td>
<td>16-19 years</td>
<td>Blood Donors</td>
<td>107,879</td>
<td>0.4% (0.4% - 0.5%)</td>
<td>Furusyo AMTM 1998</td>
</tr>
<tr>
<td>1995-2000</td>
<td>National</td>
<td>16-19 years</td>
<td>Blood Donors</td>
<td>582,415</td>
<td>0.23% (0.22% - 0.24%)</td>
<td>Tanaka Interviro 2004</td>
</tr>
<tr>
<td>2009</td>
<td>Iwate prefecture</td>
<td>5-9 years</td>
<td>School based</td>
<td>17,363</td>
<td>0.0% (0.00% - 0.04%)</td>
<td>Tanaka Interviro 2011</td>
</tr>
<tr>
<td>2005-2010</td>
<td>National</td>
<td>4-15 years</td>
<td>Serum reference bank</td>
<td>3,000</td>
<td>0.17% (0.0-0.41)</td>
<td>Kiyohara T Vaccine 2015</td>
</tr>
</tbody>
</table>

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF's Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank's World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
**KIRIBATI**

### Demographics
- **Total population (2017):** 116,398
- **Births (2017):** 3,246
- **Surviving infants (2017):** 3,105
- **Urban population (2016):** 44%

### Hepatitis B vaccine
- **HepB3 introduced nationwide:** 1995
- **HepB birth dose introduced:** 1990
- **Current schedule:** 0, 6 weeks, 10 weeks, 14 weeks
- **HepB3 type:** DTP-Hib-HepB

### WHO verification
- **Status of verifying prevalence targets:**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### Neonatal deliveries
- **Urban population (2016):** 44%

### Hepatitis B vaccination coverage

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>48-59 months</td>
<td>181</td>
<td>not reported</td>
<td>not reported</td>
<td>32%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>36-47 months</td>
<td>200</td>
<td>not reported</td>
<td>not reported</td>
<td>42%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>24-35 months</td>
<td>202</td>
<td>not reported</td>
<td>not reported</td>
<td>50%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>12-23 months</td>
<td>233</td>
<td>not reported</td>
<td>61%</td>
<td>61%</td>
<td>DHS Survey: HepB3 58%, DTP3 58% by 12 months</td>
</tr>
</tbody>
</table>

### 2017 Districts by coverage categories*

**Survey year** | **Location** | **Ages enrolled** | **Sample size** | **HBSAg prevalence (95%CI)** | **Reference/Notes** |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>156</td>
<td>3.8%</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>5-9 years</td>
<td>Community based</td>
<td>1249</td>
<td>3.3% (2.4% - 4.6%)</td>
</tr>
</tbody>
</table>

### Abbreviations:
- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBSAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics

| Total population (2017) | 6,858,160 |
| Births (2017)           | 160,698   |
| Surviving infants (2017)| 154,187   |
| Urban population (2016) | 40%       |

### Hepatitis B vaccine

- HepB3 introduced nationwide: 2001
- HepB birth dose introduced: 2004
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

### WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>12-23 months</td>
<td>828</td>
<td>not reported</td>
<td>not reported</td>
<td>41%</td>
<td>Lao PDR Multiple Indicator Cluster Survey 2006 Final Report; DTP3 32% by 12 months</td>
</tr>
<tr>
<td>2011-2012</td>
<td>National</td>
<td>12-23 months</td>
<td>2141</td>
<td>37%</td>
<td>56%</td>
<td>56%</td>
<td>Lao Social Indicator Survey (LSIS), (MICS / DHS Survey): HepB BD 37%, HepB3 52%, DTP3 52% by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>5981</td>
<td>72%</td>
<td>81%</td>
<td>81%</td>
<td>National Immunization Survey</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>National</td>
<td>5-9 years</td>
<td>Community based</td>
<td>965</td>
<td>1.7% (0.8% - 2.6%)</td>
<td>Xeuatvongsa PloS ONE 2014</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
MALAYSIA

Demographics

Total population (2017) 31 624 264
Births (2017) 536 823
Surviving infants (2017) 533 798
Urban population (2016) 75%

Hepatitis B vaccine

HepB3 introduced nationwide 1989
HepB birth dose introduced 1989
Current schedule 0, 1 month, 6 months
HepB3 type Monovalent

WHO verification

Status of verifying prevalence targets
Verification started: March 2011
Decision: <1% in children
Decision date: July 2011

Neonatal deliveries

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
1997-2007 National 6-9 years School based 193 717 0.40% MoH Malaysia 2011
2003 National 7 years School based 12 269 0.40% Ng Med Microb Imm 2005
2007 National 7-9 years Community based 1735 0.30% MoH Malaysia 2008
2009 National 9 years School based 2938 0.2% (0% - 0.3%) MoH Malaysia 2011
2009 National 10 years School based 3265 0.4% (0.2% - 0.6%) MoH Malaysia 2011

Hepatitis B vaccination coverage

Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes
1997-2007 National 6-9 years School based 193 717 0.40% MoH Malaysia 2011
2003 National 7 years School based 12 269 0.40% Ng Med Microb Imm 2005
2007 National 7-9 years Community based 1735 0.30% MoH Malaysia 2008
2009 National 9 years School based 2938 0.2% (0% - 0.3%) MoH Malaysia 2011
2009 National 10 years School based 3265 0.4% (0.2% - 0.6%) MoH Malaysia 2011

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
**Demographics**

- Total population (2017): 53,127
- Births (2017): 998
- Surviving infants (2017): 985
- Urban population (2016): 73%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1990s
- HepB birth dose introduced: 1998
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-HepB-IPV

**WHO verification**

- Status of verifying prevalence targets: pending
- Verification started: n.a.
- Decision: n.a.
- Decision date: n.a.

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>0-24 months</td>
<td>115</td>
<td>not reported</td>
<td>86%</td>
<td>65%</td>
<td>RMI Community Survey 2006: confirmation method by card only</td>
</tr>
<tr>
<td>2007</td>
<td>Majuro, Ebeye</td>
<td>5-9 years</td>
<td>331</td>
<td>49%</td>
<td>93%</td>
<td>not reported</td>
<td>Bialek Ped Infect Dis 2010</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>not reported</td>
<td>214</td>
<td>not reported</td>
<td>not reported</td>
<td>17% (for age 48-59M); 32% (for age 36-47M)</td>
<td>DHS Survey 2007: DTP3 by 12 months</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>24-35 months</td>
<td>207</td>
<td>not reported</td>
<td>not reported</td>
<td>32%</td>
<td>DHS Survey 2007: DTP3 by 12 months</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>12-23 months</td>
<td>249</td>
<td>not reported</td>
<td>not reported</td>
<td>48%</td>
<td>DHS Survey; DTP3 38% by 12 months</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>24-35 months</td>
<td>1312</td>
<td>87%</td>
<td>76%</td>
<td>72%</td>
<td>MMWR May 25, 2018 / 67(20);579-584</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Majuro, Ebeye</td>
<td>5-9 years</td>
<td>School based</td>
<td>331</td>
<td>1.8% (0.4% - 3.3%)</td>
<td>Bialek PID 2010</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>5-6 years</td>
<td>School based</td>
<td>1148</td>
<td>1.2% (0.6% - 1.9%)</td>
<td>2018 MoH Marshall Islands</td>
</tr>
</tbody>
</table>

**Total population (2017)**

- National: 53,127
- Poorest quantile: 20%
- Richest quantile: 20%

**Births (2017)**

- National: 998
- Poorest quantile: 20%
- Richest quantile: 20%

**Surviving infants (2017)**

- National: 985
- Poorest quantile: 20%
- Richest quantile: 20%

**Urban population (2016)**

- National: 73%
- Poorest quantile: 20%
- Richest quantile: 20%

**Abbreviations:** DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
# FEDERATED STATES OF MICRONESIA

## Demographics

<table>
<thead>
<tr>
<th>Total population (2017)</th>
<th>105,544</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2017)</td>
<td>2,514</td>
</tr>
<tr>
<td>Surviving infants (2017)</td>
<td>2,435</td>
</tr>
<tr>
<td>Urban population (2016)</td>
<td>22%</td>
</tr>
</tbody>
</table>

## Hepatitis B vaccine

- **HepB3 introduced nationwide:** 1988
- **HepB birth dose introduced:** 1988
- **Current schedule:** 0, 2 months, 4 months, 6 months
- **HepB3 type:** DTP-HepB-IPV

## WHO verification

- **Status of verifying prevalence targets:**
  - Verification started: October 2017
  - Decision: <1% in children
  - Decision date: March 2018

## Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>National</td>
<td>2 years</td>
<td>16,391</td>
<td>not reported</td>
<td>84%</td>
<td>not reported</td>
<td>Manea PH Reports 1992</td>
</tr>
<tr>
<td>1992</td>
<td>Chuuk</td>
<td>2 years</td>
<td>544</td>
<td>not reported</td>
<td>40%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>1994</td>
<td>Pohnpei</td>
<td>3-4 years</td>
<td>364</td>
<td>not reported</td>
<td>82%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>2000</td>
<td>Chuuk</td>
<td>2-6 years</td>
<td>365</td>
<td>50%</td>
<td>87%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2005</td>
<td>Pohnpei</td>
<td>2-9 years</td>
<td>478</td>
<td>87%</td>
<td>90%</td>
<td>not reported</td>
<td>Bialek Ped Infect Dis 2010</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>2-9 years</td>
<td>432</td>
<td>75%</td>
<td>91%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2016</td>
<td>Chuuk</td>
<td>24-25 months</td>
<td>1,218</td>
<td>54%</td>
<td>78%</td>
<td>72%</td>
<td>MMWR May 25, 2018 / 67(20);579-584</td>
</tr>
</tbody>
</table>

## Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBSAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Chuuk</td>
<td>2-6 years</td>
<td>Hospital based</td>
<td>362</td>
<td>2.5%</td>
<td>Bialek PID 2010</td>
</tr>
<tr>
<td>2005</td>
<td>Pohnpei</td>
<td>2-6 years</td>
<td>Hospital based</td>
<td>478</td>
<td>1.5%</td>
<td>Bialek PID 2010</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>5-6 years</td>
<td>School based</td>
<td>2,106</td>
<td>0.3% (0.1% - 0.5%)</td>
<td>2017 MoH Federated States of Micronesia</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBSAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*

## Neonatal deliveries

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Pohnpei</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
</tr>
</tbody>
</table>

## 2017 Districts by coverage categories*

<table>
<thead>
<tr>
<th>% District 2017</th>
<th>HepB3</th>
<th>Timely HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50%-79%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80%-89%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90%-94%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;94%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Demographics

- Total population (2017): 3,075,647
- Births (2017): 70,726
- Surviving infants (2017): 69,383
- Urban population (2016): 73%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1991
- HepB birth dose introduced: 1991
- Current schedule: 0, 2 months, 3 months, 4 months
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets
  - Verification started: April 2012
  - Decision: <1% in children
  - Decision date: July 2012

Neonatal deliveries

- Proportion of deliveries (%)
  - National average: In health facility
  - Poorest quantile: Attended by SBA
  - Richest quantile: In health facility

Hepatitis B vaccination coverage

- 2017 Districts by coverage categories *

Survey coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>National</td>
<td>12-23 months</td>
<td>1255</td>
<td>not reported</td>
<td>not reported</td>
<td>89%</td>
<td>Mongolia, Child and Development survey-2000 (MICS-2), 2001</td>
</tr>
<tr>
<td>2004</td>
<td>National</td>
<td>4-6 years</td>
<td>5894</td>
<td>95%</td>
<td>73%</td>
<td>not reported</td>
<td>MoH Mongolia 2011</td>
</tr>
<tr>
<td>2004</td>
<td>National</td>
<td>8 years</td>
<td>1145</td>
<td>65%</td>
<td>60%</td>
<td>not reported</td>
<td>Daavaalkham J Epid 2007</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>12-23 months</td>
<td>724</td>
<td>not reported</td>
<td>not reported</td>
<td>93%</td>
<td>Mongolia Child and Development 2005 Survey (MICS-3): DTP3-92% by 12M</td>
</tr>
<tr>
<td>2010</td>
<td>National</td>
<td>12-23 months</td>
<td>944</td>
<td>97%</td>
<td>not reported</td>
<td>92%</td>
<td>MIC5 : HepB BD 96.7% by 12M; DPT3 92.1% by 12M</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>12-23 months</td>
<td>1180</td>
<td>99%</td>
<td>98%</td>
<td>not reported</td>
<td>Mongolia Social Indicator Sample Survey: HepB BD 93.1%, HepB3 92.5%, DTP3 92.5% by 12M</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>24-35 months</td>
<td>1236</td>
<td>97%</td>
<td>96%</td>
<td>96%</td>
<td>Mongolia Social Indicator Sample Survey :HepB BD 86%, HepB3 84.2%, DTP3 84.2% by 12M</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>National</td>
<td>7-12 years</td>
<td>School based</td>
<td>1145</td>
<td>5.2%</td>
<td>Daavaalkham PI 2007</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>4 years</td>
<td>Community based</td>
<td>5894</td>
<td>0.34%</td>
<td>MoH Mongolia 2011</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
NAURU

Demographics

Total population (2017) 11,359
Births (2016) 400
Surviving infants (2016) 397
Urban population (2016) 100%

Hepatitis B vaccine

HepB3 introduced nationwide 1983
HepB birth dose introduced Yes, introduction year unknown
Current schedule 0, 6 weeks, 10 weeks, 14 weeks
HepB3 type DTP-Hib-HepB

WHO verification

Status of verifying prevalence targets
Verification started: pending
Decision: n.a.
Decision date: n.a.

Neonatal deliveries

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B vaccination coverage

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes

2017 Districts by coverage categories*

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys

Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

<table>
<thead>
<tr>
<th>Total population (2017)</th>
<th>276,255</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2017)</td>
<td>4,304</td>
</tr>
<tr>
<td>Surviving infants (2017)</td>
<td>4,254</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>71%</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccine**

<table>
<thead>
<tr>
<th>HepB3 introduced nationwide</th>
<th>1989</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB birth dose introduced</td>
<td>Yes, introduction year unknown</td>
</tr>
<tr>
<td>Current schedule</td>
<td>0, 2 months, 11 months</td>
</tr>
<tr>
<td>HepB3 type</td>
<td>DTP-Hib-HepB-IPV</td>
</tr>
</tbody>
</table>

**WHO verification**

<table>
<thead>
<tr>
<th>Status of verifying prevalence targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verification started</td>
</tr>
<tr>
<td>Decision</td>
</tr>
<tr>
<td>Decision date</td>
</tr>
</tbody>
</table>

**Neonatal deliveries**

- Total population (2017): 276,255
- Births (2017): 4,304
- Surviving infants (2017): 4,254
- Urban population (2016): 71%

**Hepatitis B vaccination coverage**

- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 2 months, 11 months
- HepB3 type: DTP-Hib-HepB-IPV

**WHO verification**

- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

**2017 Districts by coverage categories**

- National average
- Richest quantile
- Poorest quantile
- National average
- Richest quantile
- Poorest quantile

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
NEW ZEALAND

Demographics

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2017)</td>
<td>4,705,818</td>
</tr>
<tr>
<td>Births (2017)</td>
<td>61,807</td>
</tr>
<tr>
<td>Surviving infants (2017)</td>
<td>61,568</td>
</tr>
<tr>
<td>Urban population (2016)</td>
<td>86%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1985
- HepB3 type: DTP-Hib-HepB-IPV
- HepB birth dose introduced: If born to HBsAg+ mothers
- Current schedule: 6 weeks, 3 months, 5 months

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>12 months</td>
<td>1563</td>
<td>72%</td>
<td>82%</td>
<td>85%</td>
<td>MoH; 87% HepB3 by 2 years</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets:
  - Verification started: April 2012
  - Decision: <1% in children
  - Decision date: September 2012

Neonatal deliveries

<table>
<thead>
<tr>
<th>Sample size</th>
<th>Proportion of deliveries (%)</th>
<th>Health facility</th>
<th>Attended by SBA</th>
<th>National average</th>
<th>Poorest quantile</th>
<th>Richest quantile</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2017 Districts by coverage categories*

<table>
<thead>
<tr>
<th>District 2017</th>
<th>Timely HepB BD</th>
<th>Any HepB BD</th>
<th>HepB3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;50%</td>
<td>&lt;50%-79%</td>
<td>80%-89%</td>
</tr>
<tr>
<td></td>
<td>80%-89%</td>
<td>90%-94%</td>
<td>&gt;94%</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>North Islands</td>
<td>6 years</td>
<td>Health facility</td>
<td>466</td>
<td>0.2% (0.0% - 1.2%)</td>
<td>Weir R. MoH New Zealand 2009</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF's Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank's World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

- Total population (2017): 1618
- Births (2017): 19
- Surviving infants (2017): 19
- Urban population (2015): 43%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1986
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB-IPV

**WHO verification**

- Verification started: November 2015
- Decision: <1% in children
- Decision date: February 2017

**Neonatal deliveries**

- Total population (2017): 1618
- Births (2017): 19
- Surviving infants (2017): 19
- Urban population (2015): 43%

**Hepatitis B vaccination coverage**

- HepB3 introduced nationwide: 1986
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB-IPV

**2017 Districts by coverage categories**

**Vaccination coverage surveys**

- Survey year: 2015
- Location: National
- Ages enrolled: 5-12 years
- Sample size: 183
- HepB %: 0.0%
- HepB3 %: 0.0%
- DTP3 %: 0.0%

**Hepatitis B serological surveys**

- Survey year: 2015
- Location: National
- Ages enrolled: 5-12 years
- Sampling base: School based
- Sample size: 183
- HBsAg prevalence (95%CI): 0.0%
- Reference/Notes: Patel Vaccine 2016

**Abbreviations:** DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
NORTHERN MARIANA ISLANDS, COMMONWEALTH OF THE

Demographics
Total population (2017) 55,144
Births (2017) 1,209
Surviving infants (2017) 1,202
Urban population (2016) 89%

Hepatitis B vaccine
HepB3 introduced nationwide 1988
HepB birth dose introduced 1988
Current schedule 0, 6 weeks, 4 months, 6 months
HepB3 type DTP-HepB-IPV

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
1995 National 3-4 years 200 not reported 94% not reported Mahoney Pac Hth Dialog 1996
2005 National 19-35 months 295 100% 94% not reported
2016 National 24-35 months 1,140 98% 62% 60% MMWR May 25, 2018 / 67(20);579-584

WHO verification
Status of verifying prevalence targets
Verification started: December 2015
Decision: <1% in children
Decision date: April 2017

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBSAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
### Demographics
- Total population (2017): 21,729
- Births (2017): 232
- Surviving infants (2017): 229
- Urban population (2016): 88%

### Hepatitis B vaccine
- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 2 months, 6 months
- HepB3 type: DTP-HepB-IPV

#### WHO verification
- Status of verifying prevalence targets
  - Verification started: January 2013
  - Decision: <1% in children
  - Decision date: May 2013

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>10-11 years</td>
<td>192</td>
<td>100%</td>
<td>85%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>24-35 months</td>
<td>259</td>
<td>97%</td>
<td>93%</td>
<td>95%</td>
<td>MMWR May 25, 2018 / 67(20);579-584</td>
</tr>
</tbody>
</table>

### Neonatal deliveries

#### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>10-11 years</td>
<td>Community based</td>
<td>192</td>
<td>0%</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2008</td>
<td>Main Island</td>
<td>5-7 years</td>
<td>School based</td>
<td>143</td>
<td></td>
<td>MoH Palau 2013</td>
</tr>
</tbody>
</table>

### Abbreviations:
- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine;
- HepB3: at least 3 doses of hepatitis B vaccine;
- HBsAg: hepatitis B surface antigen;
- SBA: Skilled Birth Attendant;
- Timely HepB BD: birth dose within 24 hours

### Sources:
- Total population was from the United Nations World Population Prospects the 2017 revision;
- Urban Population was derived from World Bank;
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data);
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
PAPUA NEW GUINEA

Demographics

- **Total population (2017)**: 8,251,162
- **Births (2017)**: 225,434
- **Surviving infants (2017)**: 215,204
- **Urban population (2016)**: 13%

Hepatitis B vaccine

- **HepB3 introduced nationwide**: 1989
- **HepB birth dose introduced**: ~2003
- **Current schedule**: 0, 1 month, 2 months, 3 months
- **HepB3 type**: DTP-Hib-HepB

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2005-2006 | National | 12-23 months | 2137 | not reported | 65% | 67% | National Immunization Coverage Survey

WHO verification

- **Status of verifying prevalence targets**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Neonatal deliveries

- **Urban population (2016)**: 13%
- **HepB3 introduced nationwide**: 1989
- **HepB birth dose introduced**: ~2003
- **Current schedule**: 0, 1 month, 2 months, 3 months
- **HepB3 type**: DTP-Hib-HepB

Survey year | Location | Ages enrolled | Sample size | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
1989-1990 | Port Moresby | 3-5 months | 31 | 13% | Nemba ATPaed. 1993
2012-2013 | National | 4-6 years | 2109 | 2.3% | Kitau ASTMH 2015

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005-2006</td>
<td>National</td>
<td>12-23 months</td>
<td>2137</td>
<td>not reported</td>
<td>65%</td>
<td>67%</td>
<td>National Immunization Coverage Survey</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989-1990</td>
<td>Port Moresby</td>
<td>3-5 months</td>
<td>Hospital Based</td>
<td>31</td>
<td>13%</td>
<td>Nemba ATPaed. 1993</td>
</tr>
<tr>
<td>2012-2013</td>
<td>National</td>
<td>4-6 years</td>
<td>Community based</td>
<td>2109</td>
<td>2.3%</td>
<td>Kitau ASTMH 2015</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

- Total population (2017): 104,918,090
- Births (2017): 2,411,184
- Surviving infants (2017): 2,363,576
- Urban population (2016): 44%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1991
- HepB birth dose introduced: 2007
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

**WHO verification**

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998-1999</td>
<td>National</td>
<td>12-23 months</td>
<td>1474</td>
<td>not reported</td>
<td>not reported</td>
<td>81%</td>
<td>DHS Survey: DTP3 79% by 12 months</td>
</tr>
<tr>
<td>2000</td>
<td>National</td>
<td>12-23 months</td>
<td>2227</td>
<td>not reported</td>
<td>32%</td>
<td>80%</td>
<td>Philippines, Maternal and Child Health Survey 2000</td>
</tr>
<tr>
<td>2002</td>
<td>National</td>
<td>12-23 months</td>
<td>1885</td>
<td>not reported</td>
<td>not reported</td>
<td>81%</td>
<td>Philippines, Maternal and Child Health Survey 2002</td>
</tr>
<tr>
<td>2003</td>
<td>National</td>
<td>12-23 months</td>
<td>1348</td>
<td>not reported</td>
<td>not reported</td>
<td>79%</td>
<td>DHS Survey: DTP3 75% by 12 months</td>
</tr>
<tr>
<td>2008</td>
<td>National</td>
<td>12-23 months</td>
<td>1286</td>
<td>not reported</td>
<td>80%</td>
<td>86%</td>
<td>DHS Survey (NDHS) 2008: by 12 months (HepB3 76%, DTP3 83%)</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>12-23 months</td>
<td>1397</td>
<td>not reported</td>
<td>78%</td>
<td>86%</td>
<td>DHS Survey, 2013: by 12 months (HepB3 74%, DTP3 85%)</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
**Demographics**

- **Total population (2017)**: 50,982,212
- **Births (2017)**: 451,370
- **Surviving infants (2017)**: 450,279
- **Urban population (2016)**: 83%

**Hepatitis B vaccine**

- **HepB3 introduced nationwide**: 1983
- **HepB birth dose introduced**: 1983
- **Current schedule**: 0, 1 month, 6 months
- **HepB3 type**: Monovalent

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>National</td>
<td>0-6 years</td>
<td>1026</td>
<td>100%</td>
<td>93%</td>
<td>95%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>19-35 months</td>
<td>not reported</td>
<td>not reported</td>
<td>99%</td>
<td>99%</td>
<td>2009 Korea National Immunization Survey (Confirmation method NA)</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>0-3 years</td>
<td>7040</td>
<td>99%</td>
<td>98%</td>
<td>93%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>10-14 years</td>
<td>Community based</td>
<td>594</td>
<td>0.2% (0.0% - 0.6%)</td>
<td>CDC Korea 2008</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>4-6 years</td>
<td>Hospital based</td>
<td>2920</td>
<td>0.2% (0.0% - 0.4%)</td>
<td>CDC Korea 2008</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>10-18 years</td>
<td>Community based</td>
<td>510</td>
<td>0.1%</td>
<td>KNHANES 2014</td>
</tr>
</tbody>
</table>

**WHO verification**

- **Status of verifying prevalence targets**
  - **Verification started**: January 2008
  - **Decision**: <1% in children
  - **Decision date**: June 2008

**Abbreviations**: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
Demographics

- Total population (2017): 196,440
- Births (2017): 4,772
- Surviving infants (2017): 4,694
- Urban population (2016): 19%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Neonatal deliveries

- Proportion of deliveries (%): National average, Poorest quantile, Richest quantile

Hepatitis B vaccination coverage

- Vaccination coverage (%): National average, Poorest quantile, Richest quantile

2017 Districts by coverage categories*

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>12-24 months</td>
<td>321</td>
<td>70%</td>
<td>not reported</td>
<td>not reported</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>18-29 months</td>
<td>321</td>
<td>not reported</td>
<td>not reported</td>
<td>38%</td>
<td>DHS Survey: 37% DTP3 by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>48-59 months</td>
<td>559</td>
<td>75%</td>
<td>45%</td>
<td>45%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>36-47 months</td>
<td>605</td>
<td>81%</td>
<td>50%</td>
<td>50%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>24-35 months</td>
<td>680</td>
<td>82%</td>
<td>54%</td>
<td>54%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>674</td>
<td>84%</td>
<td>64%</td>
<td>64%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>18-29 months</td>
<td>666</td>
<td>83%</td>
<td>64%</td>
<td>64%</td>
<td>DHS Survey; by 18 months 83% HepB, 63% HepB3 and 63% DTP3</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>National</td>
<td>5-6 years</td>
<td>School based</td>
<td>1776</td>
<td>0.11%</td>
<td>MoH Samoa 2015</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
SINGAPORE

Demographics

Total population (2017) 5,708,844
Births (2017) 49,793
Surviving infants (2017) 49,700
Urban population (2016) 100%

Hepatitis B vaccine

HepB3 introduced nationwide 1985
HepB birth dose introduced 1987
Current schedule 0, 1 month, 5 months
HepB3 type Monovalent

WHO verification

Status of verifying prevalence targets
Verification started: April 2015
Decision: <1% in children
Decision date: October 2015

Neonatal deliveries

Vaccination coverage surveys

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2007 National 2 years 31,778 not reported 94%-96% 97%

Hepatitis B serological surveys

Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes
1998-1999 National 0-4 years not reported 229 0% Epi News Bull SNG 2000
2008-2010 Two public hospitals 1-17 years Hospital based 1,200 0.3% (0.1%-0.9%) Ang J Med Virol 2013

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
### Demographics
- Total population (2017): 611,343
- Births (2017): 17,246
- Surviving infants (2017): 16,812
- Urban population (2016): 23%

### Hepatitis B vaccine
- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: ~2005
  - Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
  - HepB3 type: DTP-Hib-HepB

### WHO verification
- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### Neonatal deliveries

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>48-59 months</td>
<td>477</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>36-47 months</td>
<td>515</td>
<td>not reported</td>
<td>not reported</td>
<td>81%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>24-35 months</td>
<td>533</td>
<td>not reported</td>
<td>not reported</td>
<td>80%</td>
<td>DHS Survey (DTP3 by 12 months)</td>
</tr>
<tr>
<td>2006-2007</td>
<td>National</td>
<td>12-23 months</td>
<td>535</td>
<td>not reported</td>
<td>not reported</td>
<td>88%</td>
<td>DHS Survey (87% DTP3 by 12 months)</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>Guadalcanal Islands</td>
<td>0-9 years</td>
<td>Hospital based</td>
<td>115</td>
<td>13%</td>
<td>Furusyo Am J Trop 1999</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>6-7 years</td>
<td>School based</td>
<td>1169</td>
<td>3.1% (2.0% - 4.9%)</td>
<td>Preliminary data</td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

### Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

### Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
TOKELAU

Demographics

<table>
<thead>
<tr>
<th>Total population (2017)</th>
<th>1300</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2017)</td>
<td>15</td>
</tr>
<tr>
<td>Surviving infants (2017)</td>
<td>15</td>
</tr>
<tr>
<td>Urban population (2015)</td>
<td>0%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

<table>
<thead>
<tr>
<th>HepB3 introduced nationwide</th>
<th>1990</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB birth dose introduced</td>
<td>1990</td>
</tr>
<tr>
<td>Current schedule</td>
<td>0, 6 weeks, 10 weeks, 14 weeks</td>
</tr>
<tr>
<td>HepB3 type</td>
<td>DTP-Hib-HepB</td>
</tr>
</tbody>
</table>

WHO verification

<table>
<thead>
<tr>
<th>Status of verifying prevalence targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verification started: May 2015</td>
</tr>
<tr>
<td>Decision: &lt;1% in children</td>
</tr>
<tr>
<td>Decision date: June 2016</td>
</tr>
</tbody>
</table>

Neonatal deliveries

- Proportion of deliveries (%)
  - National average
  - Poorest quantile
  - Richest quantile
  - National average
  - Poorest quantile
  - Richest quantile

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
-------------|----------|---------------|-------------|-----------|---------|--------|-------------------------
2013         | National | 6-12 years    | 171         | 80%       | 70%     | 70%    | Patel Vaccine 2016

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
-------------|----------|---------------|---------------|-------------|--------------------------|-------------------------
2014         | National | 6-12 years    | School based  | 171         | 0.0%                     | Patel Vaccine 2016

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

- Total population (2017): 108,020
- Births (2017): 2,559
- Surviving infants (2017): 2,509
- Urban population (2016): 24%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets
  - Verification started: May 2011
  - Decision: <2% in children
  - Decision date: January 2012

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>12-23 months</td>
<td>114</td>
<td>not reported</td>
<td>94%</td>
<td>96%</td>
<td>Evaluation of Immunization Program of the Kingdom of Tonga</td>
</tr>
<tr>
<td>2005</td>
<td>Tongatapu hospital</td>
<td>6-59 months</td>
<td>445</td>
<td>92%</td>
<td>98%</td>
<td>98%</td>
<td>Danielsson Vaccine 2009</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>48-59 months</td>
<td>302</td>
<td>not reported</td>
<td>61%</td>
<td>61%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>36-47 months</td>
<td>334</td>
<td>not reported</td>
<td>59%</td>
<td>59%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>24-35 months</td>
<td>383</td>
<td>not reported</td>
<td>60%</td>
<td>60%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>12-23 months</td>
<td>307</td>
<td>not reported</td>
<td>66%</td>
<td>66%</td>
<td>DHS Survey (65% HepB3 and 65% DTP3 by 12 months)</td>
</tr>
</tbody>
</table>

Neonatal deliveries

<table>
<thead>
<tr>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>114</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2005</td>
<td>375</td>
<td>Danielsson Vaccine 2009</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>211</td>
<td>3.8%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2005</td>
<td>Main Island</td>
<td>6-59 months</td>
<td>Hospital based</td>
<td>375</td>
<td>0.8% (0.2% - 2.5%)</td>
<td>Danielsson Vaccine 2009</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
TUVALU

Demographics
Total population (2017) 11 192
Births (2017) 233
Surviving infants (2017) 280
Urban population (2016) 61%

Hepatitis B vaccine
HepB3 introduced nationwide Yes, introduction year unknown
HepB birth dose introduced Yes, introduction year unknown
Current schedule 0, 6 weeks, 10 weeks, 14 weeks
HepB3 type DTP-Hib-HepB

Vaccination coverage surveys
Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2007 National 48-59 months 75 not reported not reported 59% DHS Survey (DTP3 by 18 months)
2007 National 36-47 months 84 not reported not reported 57% DHS Survey (DTP3 by 18 months)
2007 National 24-35 months 89 not reported not reported 60% DHS Survey (DTP3 by 18 months)
2007 National 18-29 months 80 not reported not reported 62% DHS Survey (60% DTP3 by 18 months)

WHO verification
Status of verifying prevalence targets
Verification started: pending
Decision: n.a.
Decision date: n.a.

Neonatal deliveries
TUVALU

2017 Districts by coverage categories*

Hepatitis B vaccination coverage

Survey year Location Ages enrolled Sample size HBsAg prevalence (95%CI) Reference/Notes
1976 Fanafuti 10-19 years Community based 181 11% Gust JID 1979

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

- Total population (2017): 276,244
- Births (2017): 7,054
- Surviving infants (2017): 6,902
- Urban population (2016): 26%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989-1990
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Neonatal deliveries

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2007 | National | 12-23 months | 359 | not reported | 59% | 63% | MICS; by 12 months 55% HepB3, 58% DTP3
2013 | National | 12-23 months | 303 | not reported | 55% | 55% | DHS Survey; by 12 months 49% HepB3, 49% DTP3

Hepatitis B vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2017 Districts by coverage categories*

VANUATU

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
1988 | Emao or Nguna | 12-18 months | Community based | 112 | 17% | Maher Med J Aust 1991
1998 | Large Towns | 12-24 months | Hospital based | 132 | 3.0% | Wilson Vaccine 2000

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
1988 | Emao or Nguna | 12-18 months | Community based | 112 | 17% | Maher Med J Aust 1991
1998 | Large Towns | 12-24 months | Hospital based | 132 | 3.0% | Wilson Vaccine 2000

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

- Total population (2017): 95,540,800
- Births (2017): 1,570,352
- Surviving infants (2017): 1,543,906
- Urban population (2016): 34%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1997
- HepB birth dose introduced: 2005
- Current schedule: 0, 2 months, 3 months, 4 months
- HepB3 type: DTP-Hib-HepB

**WHO verification**

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

**Neonatal deliveries**

**Hepatitis B vaccination coverage**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>National</td>
<td>12-24 months</td>
<td>457</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2006</td>
<td>National</td>
<td>12-23 months</td>
<td>555</td>
<td>not reported</td>
<td>34%</td>
<td>79%</td>
<td>MICS; 32% HepB3 and 76% DTP3 by 12 months</td>
</tr>
<tr>
<td>2002-2003</td>
<td>National</td>
<td>12-23 months</td>
<td>457</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2010-2011</td>
<td>National</td>
<td>12-23 months</td>
<td>759</td>
<td>not reported</td>
<td>56%</td>
<td>74%</td>
<td>MICS; 53% HepB3 and 73% DTP3 by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>24-35 months</td>
<td>641</td>
<td>71%</td>
<td>92%</td>
<td>93%</td>
<td>MICS; 71% HepB BD, 92% HepB3 and 93% DTP3 by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>12-23 months</td>
<td>790</td>
<td>78%</td>
<td>87%</td>
<td>89%</td>
<td>MICS; 78% HepB BD, 87% HepB3 and 89% DTP3 by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>2417</td>
<td>56%</td>
<td>98%</td>
<td>85%</td>
<td>WHO-UNICEF Joint Reporting Form (data for 2017)</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Thanh Hoa</td>
<td>9-18 months</td>
<td>Community based</td>
<td>536</td>
<td>12.5%</td>
<td>Hipgrave AJTMH 2003</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>3-4 years</td>
<td>Community based</td>
<td>3426</td>
<td>1.6% (1.25%-2.15%)</td>
<td>Nguyen Vaccine 2014</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>5-7 years</td>
<td>Community based</td>
<td>1738</td>
<td>2.2% (1.47%-3.14%)</td>
<td>Nguyen Vaccine 2014</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>8-11 years</td>
<td>Community based</td>
<td>1740</td>
<td>3.6% (2.80%-4.71%)</td>
<td>Nguyen Vaccine 2014</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**WALLIS AND FUTUNA**

### Demographics

- Total population (2017): 11,773
- Births (2017): 157
- Surviving infants (2017): 152
- Urban population (2015): 0%

### Hepatitis B vaccine

- HepB3 introduced nationwide: Yes, introduction year unknown
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 2 months, 11 months
- HepB3 type: DTP-Hib-HepB-IPV

### WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### Neonatal deliveries

- Total population (2017): 11,773
- Births (2017): 157
- Surviving infants (2017): 152
- Urban population (2015): 0%

### Hepatitis B vaccination coverage

- **2017 Districts by coverage categories***

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>National</td>
<td>7-12 years</td>
<td>442</td>
<td>not reported</td>
<td>94%</td>
<td>not reported</td>
<td>Data from national serosurvey</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>National</td>
<td>9-11 years</td>
<td>School-based</td>
<td>428</td>
<td>0.93%</td>
<td>Preliminary data</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.